On Monday, in the course of current trade, Shares of Frontier Communications Corporation (NASDAQ:FTR), dropped -1.21%, and is now trading at $5.09.
Frontier Communications Corporation, has declared a discount program in response to hundreds of layoffs by MinnTac, Mesabi Nugget and Mining Resources. Frontier is reducing the cost of High-Speed Internet access for affected employees who are current customers.
Many employees of MinnTac, Mesabi Nugget and Mining Resources are being laid off as a downturn in the steel industry caused production cutbacks. Employees of these companies who can document they have been laid off are eligible for a $15 monthly discount on Frontier’s Internet service from July 1 to December 31, 2015. Enrollment starts June 1 and closes June 30, 2015.
Frontier Communications Corporation, a communications company, provides regulated and unregulated voice, data, and video services to residential, business, and wholesale customers in the United States.
During an Early trade, Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX), gained 4.96%, and is now trading at $20.74 .
Heron Therapeutics, declared positive, top-line results from its recently accomplished Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Company’s 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
The MAGIC study is the only Phase 3 CINV prophylaxis study in a HEC population performed to-date to use as a comparator the presently recommended, standard-of-care, three-drug regimen: a 5-HT3 receptor antagonist (in this case ondansetron), fosaprepitant and dexamethasone. The study was conducted entirely in the U.S. and enrolled over 900 patients undergoing HEC treatment for various tumor types.
The primary endpoint in this study was the proportion of patients who achieved a Complete Response, defined as no emesis and no rescue medications during the delayed-onset phase of CINV, occurring 24-120 hours following administration of HEC agents. The study’s major efficacy findings comprise:
- The study’s primary endpoint was achieved. The percentage of patients who achieved a Complete Response was significantly higher in the SUSTOL group than the comparator group (64.7% vs. 56.6%, p=0.014).
- The percentage of patients who achieved Complete Control, defined as Complete Response plus no more than mild nausea during the delayed-onset phase, also reached statistical significance in favor of SUSTOL (p = 0.022).
- The percentage of patients who practiced no nausea or infrequent nausea during the delayed-onset phase was significantly higher in the SUSTOL arm contrast with the comparator arm (p = 0.032).
- Significantly more patients in the SUSTOL arm were satisfied with their therapy based on a quality-of-life questionnaire (p = 0.040).
Heron Therapeutics, Inc. is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company’s proprietary Biochronomer drug delivery technology is designed to improve the therapeutic profile of injectable pharmaceuticals.
Shares of The Bank of New York Mellon Corporation (NYSE:BK), during its Monday’s current trading session fell -0.67%, and is now trading at $43.07.
The Bank of New York Mellon Corporation, will present at two early June conferences: Deutsche Bank’s Global Financial Services Conference on June 3 and the Morgan Stanley Financials Conference on June 10.
Gerald L. Hassell, chairman and chief executive officer of BNY Mellon, and Thomas P. Gibbons, vice chairman and chief financial officer of BNY Mellon, will be presenting at the 2015 Deutsche Bank Global Financial Services Conference in New York at 8:10 a.m. ET on Wednesday, June 3. They will talk about BNY Mellon’s corporate strategy, opportunities for growth and capital administration.
The Bank of New York Mellon Corporation, an investment company, provides financial products and services to institutions, corporations, and high net worth individuals in the United States and internationally. It operates through two segments, Investment Administration and Investment Services.
Oil prices pulled back Monday from their surge in the previous session as investors took profits and the dollar strengthened, and the market looked ahead to Friday’s meeting of the world’s oil cartel.
On Monday, light, sweet crude for July delivery was down 60 cents, or 1%, at $59.70 a barrel on the New York Mercantile Exchange. The global Brent crude contract was down 76 cents, or 1.1%, at $64.80 a barrel on the ICE Futures Europe exchange.
Denbury Resources Inc. (NYSE:DNR), lost -1.63% Monday. The company exchanged hands with 1,095,296 shares as compared to its average daily volume of 12,455,100 shares. The company has the market capitalization of 2.56B.
Denbury Resources Inc. operates as an independent oil and natural gas company in the United States. The company primarily focuses on improved oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
